Taysha Gene Financials
| TSHA Stock | USD 3.24 0.24 8.00% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.51 | 0.5406 |
|
| |||||
| Current Ratio | 3.87 | 4.0774 |
|
|
The essential information of the day-to-day investment outlook for Taysha Gene includes many different criteria found on its balance sheet. An individual investor should monitor Taysha Gene's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Taysha Gene.
Net Income |
|
Taysha | Select Account or Indicator |
Please note, the presentation of Taysha Gene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Taysha Gene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Taysha Gene's management manipulating its earnings.
Taysha Gene Stock Summary
Taysha Gene competes with Biomea Fusion, Stoke Therapeutics, Akero Therapeutics, Gossamer Bio, and X4 Pharmaceuticals. Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company was incorporated in 2019 and is based in Dallas, Texas. Taysha Gene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 178 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US8776191061 |
| CUSIP | 877619106 |
| Location | Texas; U.S.A |
| Business Address | 3000 Pegasus Park |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.tayshagtx.com |
| Phone | 214 612 0000 |
| Currency | USD - US Dollar |
Taysha Gene Key Financial Ratios
| Return On Equity | -1.15 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (11.78) % | ||||
| Price To Sales | 66.97 X | ||||
| Revenue | 15.45 M |
Taysha Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Taysha Gene's current stock value. Our valuation model uses many indicators to compare Taysha Gene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Taysha Gene competition to find correlations between indicators driving Taysha Gene's intrinsic value. More Info.Taysha Gene Therapies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Taysha Gene's Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taysha Gene's earnings, one of the primary drivers of an investment's value.Taysha Gene Therapies Systematic Risk
Taysha Gene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Taysha Gene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Taysha Gene Therapies correlated with the market. If Beta is less than 0 Taysha Gene generally moves in the opposite direction as compared to the market. If Taysha Gene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Taysha Gene Therapies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Taysha Gene is generally in the same direction as the market. If Beta > 1 Taysha Gene moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Taysha Gene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Taysha Gene's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Taysha Gene growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Taysha Gene December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Taysha Gene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Taysha Gene Therapies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Taysha Gene Therapies based on widely used predictive technical indicators. In general, we focus on analyzing Taysha Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Taysha Gene's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.19 | |||
| Information Ratio | 0.1009 | |||
| Maximum Drawdown | 55.88 | |||
| Value At Risk | (9.25) | |||
| Potential Upside | 12.25 |
Complementary Tools for Taysha Stock analysis
When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |